SWS Medical(SH:688410) Sou Hu Cai Jing·2025-08-14 13:56Core Viewpoint - The company, Chongqing Shanwaishan Blood Purification Technology Co., Ltd., has reported a decline in stock price and a high rolling price-to-earnings (PE) ratio compared to its industry peers, indicating potential overvaluation despite positive revenue and profit growth in the latest quarterly report [1][2]. Company Overview - The main business of the company includes the research, production, and sales of blood purification equipment and consumables, as well as providing chain blood dialysis medical services [1]. - Key products include blood perfusion machines, continuous blood purification devices, blood dialysis machines, and various blood purification consumables [1]. - The company has received multiple national and provincial awards for its technological advancements and has been recognized as a national innovative enterprise by the Ministry of Science and Technology [1]. Financial Performance - For the first quarter of 2025, the company achieved an operating income of 189 million yuan, representing a year-on-year increase of 16.77% [2]. - The net profit for the same period was approximately 37.01 million yuan, reflecting a year-on-year growth of 8.10% [2]. - The sales gross margin stood at 46.72% [2]. Market Position - As of the latest data, the company's rolling PE ratio is 74.59, significantly higher than the industry average of 55.76 and the industry median of 39.14, placing it at the 95th position among its peers [1][2]. - The total market capitalization of the company is approximately 5.494 billion yuan [1]. Institutional Holdings - As of the first quarter of 2025, there are 11 institutions holding shares in the company, all of which are funds, with a total holding of approximately 6.31 million shares valued at around 90 million yuan [1].